The Frontier Innovation for Cardiometabolic Disease Programme, backed by £10m from UK Research and Innovation's Local Innovation Partnerships Fund, supported by the Mayor of London, brings together partners across London to accelerate the development, validation and adoption of innovations for heart disease, diabetes and obesity.
Howard Dawber, Deputy Mayor of London for Business and Growth, said: ‘This collaboration can help pioneer new technologies and treatments, potentially saving lives and improving care for thousands of Londoners, while strengthening our world-leading life sciences sector.'
The initiative comprises two complementary £5m programmes: Venture Builder and Validate and Scale.
The Venture Builder programme will support the creation and growth of new ventures developing therapeutics, through BioInnovation Institute, one of Europe's leading innovation institutes backed by Novo Nordisk Foundation, and medical technologies, through King's College London's London Institute for Healthcare Engineering, with King's Health Partners also contributing to the wider programme.
The Validate and Scale programme is a partnership between private healthcare providers and the NHS that will enable companies to test new solutions to priority cardiometabolic challenges in real clinical settings, including the Harley Street Health District, generating evidence to support adoption in the NHS, reaching patients across London.
UCLPartners is leading this work collaboration with Harley Street Health District, Imperial College Health Partners and Health Innovation Network South London. The London Health Innovation networks are helping connect proven innovations with NHS systems.
